"DNA Topoisomerase IV" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Topoisomerase IV binds to DNA as a heterotetramer consisting 2 parC and 2 parE subunits. Topoisomerase IV is a decatenating enzyme that resolves interlinked daughter chromosomes following DNA replication.
| Descriptor ID |
D027101
|
| MeSH Number(s) |
D08.811.399.403.741.224 D12.776.097.256
|
| Concept/Terms |
parC Protein- parC Protein
- parC Gene Product, Topo IV
- Topoisomerase IV Subunit A
- parC Gene Product
parE Protein- parE Protein
- parE Gene Product, Topo IV
- Topoisomerase IV Subunit B
- parE Gene Product
|
Below are MeSH descriptors whose meaning is more general than "DNA Topoisomerase IV".
Below are MeSH descriptors whose meaning is more specific than "DNA Topoisomerase IV".
This graph shows the total number of publications written about "DNA Topoisomerase IV" by people in this website by year, and whether "DNA Topoisomerase IV" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Topoisomerase IV" by people in Profiles.
-
Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2000 Nov; 44(11):3229-31.
-
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 2000 Feb; 44(2):462-6.
-
Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol. 1999 Dec; 26(3-4):281-7.
-
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob Agents Chemother. 1999 Oct; 43(10):2513-6.
-
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug; 43(8):2051-5.
-
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother. 1998 May; 42(5):1249-52.
-
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr; 41(4):481-4.
MeSH information
